{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:36Z","timestamp":1787030136174,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Seqirus (United States)","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>A cell-based process may be better suited for vaccine production during a highly pathogenic avian influenza (HPAI) pandemic. This was a phase 3, randomized, controlled, observer-blind, multicenter study evaluated safety, immunogenicity, and lot-to-lot consistency of two doses of a MF59-adjuvanted, H5N1 influenza pandemic vaccine manufactured on a cell culture platform (aH5N1c) in 3196 healthy adult subjects, stratified into two age groups: 18 to &lt;65 and \u226565 years. Immunogenicity was measured using hemagglutination inhibition (HI) titers. HI antibody responses increased after the first aH5N1c vaccine dose, and 3 weeks after the second vaccination (Day 43), age-appropriate US Center for Biologics Evaluation and Research (CBER) and former European Medicines Authority Committee for Medicinal Products for Human Use (EMA CHMP) immunogenicity criteria were met. Six months after the first vaccination, HI titers were above baseline but no longer met CBER and CHMP criteria. No relevant changes over time were seen in placebo subjects. Solicited AEs were more frequent in the active treatment than the placebo group, primarily due to injection site pain. No serious adverse events (SAEs) related to aH5N1c- were reported. aH5N1c influenza vaccine elicited high levels of antibodies following two vaccinations administered 21 days apart and met both CBER and former CHMP immunogenicity criteria at Day 43 among both younger and older adults with a clinically acceptable safety profile. Consistency of the three consecutive aH5N1c vaccine lots was demonstrated (NCT02839330).<\/jats:p>","DOI":"10.3390\/vaccines10040497","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T22:08:06Z","timestamp":1648073286000},"page":"497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects"],"prefix":"10.3390","volume":"10","author":[{"given":"James","family":"Peterson","sequence":"first","affiliation":[{"name":"J. Lewis Research, Inc., Salt Lake City, UT 84109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6493-3393","authenticated-orcid":false,"given":"Esther","family":"Van Twuijver","sequence":"additional","affiliation":[{"name":"Clinical Development, Seqirus, Inc., 1105 BJ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Versage","sequence":"additional","affiliation":[{"name":"Clinical Development, Seqirus, Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hohenboken","sequence":"additional","affiliation":[{"name":"Clinical Development, Seqirus, Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1086\/375056","article-title":"Pandemic Influenza and the Global Vaccine Supply","volume":"36","author":"Fedson","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2021, April 12). 2009 H1N1 Pandemic (H1N1pdm09 Virus), Available online: https:\/\/www.cdc.gov\/flu\/pandemic-resources\/2009-h1n1-pandemic.html."},{"key":"ref_3","unstructured":"Knobler, S., Mahmoud, A., Lemon, S., Mack, A., and Sivitz, L.K.O. (2004). Are we ready for Pandemic Influenza?. Learning from SARS: Preparing for the Next Disease Outbreak Workshop Summary, The National Academies Press."},{"key":"ref_4","unstructured":"World Health Organization (2021, April 12). Human Infection with Avian Influenza A(H5) Viruses. Avian Influenza Weekly Update Number 784. Available online: https:\/\/www.who.int\/docs\/default-source\/wpro---documents\/emergency\/surveillance\/avian-influenza\/ai-20210319.pdf."},{"key":"ref_5","unstructured":"Homeland Security Council (2005). National Strategy for Pandemic Influenza, Department of Homeland Security."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04795","article-title":"Strategies for mitigating an influenza pandemic","volume":"442","author":"Ferguson","year":"2006","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(00)05066-2","article-title":"Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza","volume":"357","author":"Nicholson","year":"2001","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1750-2659.2008.00059.x","article-title":"MF59\u00ae-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis","volume":"2","author":"Banzhoff","year":"2008","journal-title":"Influ. Other Respir. Viruses"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.vaccine.2006.01.015","article-title":"An MF59-adjuvanted inactivated influenza vaccine containing A\/Panama\/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A\/Fujian\/2002 than a subunit and a split influenza vaccine","volume":"24","author":"Hilbert","year":"2006","journal-title":"Vaccine"},{"key":"ref_11","unstructured":"Food and Drug Administration (2007). Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines, US Department of Health and Human Services."},{"key":"ref_12","unstructured":"Committee for Medicinal Products for Human Use (1997). Note for Guidance on Harmonisation of Requirements for Influenza Vaccines, European Agency for the Evaluation of Medicinal Products."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/595832","article-title":"Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine","volume":"199","author":"Lin","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lazarus, R., Kelly, S., Snape, M.D., Vandermeulen, C., Voysey, M., Hoppenbrouwers, K., Hens, A., Van Damme, P., Pepin, S., and Leroux-Roels, I. (2016). Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165384"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/CVI.00373-12","article-title":"Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A\/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects","volume":"19","author":"Bihari","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Versage, E., van Twuijver, E., Jansen, W., Theeuwes, A., Sawlwin, D., and Hohenboken, M. (2021). Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A\/H5N1, Pandemic Influenza Vaccine across Four Phase II\/III Clinical Trials in Healthy Children, Adults, and Older Adults. Vaccines, 9.","DOI":"10.3390\/vaccines9121468"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4161\/hv.20248","article-title":"Homologous and heterologous antibody responses to a one-year booster dose of an MF59\u00ae: Adjuvanted A\/H5N1 pre-pandemic influenza vaccine in pediatric subjects","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/INF.0000000000002345","article-title":"Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A\/H5N1, Subunit Influenza Virus Vaccine: Results from a Dose-finding Clinical Trial in Healthy Pediatric Subjects","volume":"38","author":"Chanthavanich","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1473-3099(13)70046-X","article-title":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: A phase 3 randomised trial","volume":"13","author":"McElhaney","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/path.2104","article-title":"Immunosenescence of ageing","volume":"211","author":"Gruver","year":"2007","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ni.2588","article-title":"Understanding immunosenescence to improve responses to vaccines","volume":"14","author":"Goronzy","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0047-6374(02)00033-7","article-title":"The frail elderly: Role of dendritic cells in the susceptibility of infection","volume":"123","author":"Uyemura","year":"2002","journal-title":"Mech. Ageing Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells","volume":"180","author":"Seubert","year":"2008","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59\u2014An innately attractive adjuvant formulation","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0804699105","article-title":"Molecular and cellular signatures of human vaccine adjuvants","volume":"105","author":"Mosca","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15ra5","DOI":"10.1126\/scitranslmed.3000624","article-title":"Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus","volume":"2","author":"Khurana","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1016\/j.ijid.2019.03.026","article-title":"Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults \u226565 years of age: Meta-analysis of cumulative clinical experience","volume":"85s","author":"Nicolay","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3201\/eid1401.061283","article-title":"Cross-subtype Immunity against Avian Influenza in Persons Recently Vaccinated for Influenza","volume":"14","author":"Gioia","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Banzhoff, A., Gasparini, R., Laghi-Pasini, F., Staniscia, T., Durando, P., Montomoli, E., Capecchi, P.L., di Giovanni, P., Sticchi, L., and Gentile, C. (2009). MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE, 4.","DOI":"10.1371\/annotation\/5f2ae0fb-53f1-48c2-aa19-9114765ba029"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2014.07.013","article-title":"Comparison of the safety and immunogenicity of an MF59\u00ae-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1473-3099(20)30694-0","article-title":"Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: A randomised, controlled, multicentre, phase 3 efficacy study","volume":"21","author":"Beran","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","unstructured":"World Health Organization (2017). Report Prepared for the WHO Annual Consultation on the Composition of Influenza Vaccine for the Northern Hemisphere 2017\u20132018, WHO."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wu, N.C., Zost, S.J., Thompson, A.J., Oyen, D., Nycholat, C.M., McBride, R., Paulson, J.C., Hensley, S.E., and Wilson, I.A. (2017). A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLOS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006682"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.15585\/mmwr.mm6639a3","article-title":"Update: Influenza Activity\u2014United States and Worldwide, May 21\u2013September 23, 2017","volume":"66","author":"Blanton","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/ofid\/ofy209.164","article-title":"2556. Retrospective Evaluation of Mismatch from Egg-Based Isolation of Influenza Strains Compared with Cell-Based Isolation and the Possible Implications for Vaccine Effectiveness","volume":"5","author":"Rajaram","year":"2018","journal-title":"Open Forum Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/4\/497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:41:57Z","timestamp":1760136117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/4\/497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["vaccines10040497"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10040497","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]}}}